DCCRX Mutual Fund

DCCRX Mutual Fund

NAV$31.35
See how much of DCCRX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$21M
Expense Ratio
1.29%
Dividend Yield (Current)
-
Holdings
143
Inception Date
Aug 1, 2005
Fund Family
Nomura Asset Management Co Ltd
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
SEC 30-Day Yield
PRO

Performance

YTD+11.41%
1 Year+14.32%
3 Year+12.51%
5 Year+7.59%
10 Year+10.80%

Asset Allocation

Stocks: 99.15%
Cash: 0.85%
See how much of DCCRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
TVTXTravere Therapeutics Inc1.99%
LGNDLigand Pharmaceuticals, Inc.1.83%
IMX:SGImax Corp1.62%
SUPNSupernus Pharmaceuticals Inc1.62%
FSSFederal Signal Corp1.50%
Top 10 Concentration: 15.49%Report Date: Aug 31, 2026
Download all 143 holdings for DCCRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Latest Distribution
$1.93
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

DCCRX Mutual Fund Overview

DCCRX Mutual Fund (Nomura Small Cap Core Fund Class R) is managed by Nomura Asset Management Co Ltd with $20.8M in net assets. DCCRX expense ratio is 1.29%, holding 143 positions across sectors including Health Care, Financials, Industrials. Inception date: 2005-08-01.

DCCRX performance shows a YTD return of 11.41%. The 1-year return is 14.32% and the 5-year return is 7.59%.

DCCRX top holdings include Travere Therapeutics Inc (2.0%), Ligand Pharmaceuticals, Inc. (1.8%), Imax Corp (1.6%), Supernus Pharmaceuticals Inc (1.6%), Federal Signal Corp (1.5%). Go to all DCCRX holdings, DCCRX sectors, or DCCRX dividends.

DCCRX can be compared against other funds. Use DCCRX overlap to find shared positions, or DCCRX vs another fund for a side-by-side view. DCCRX alternatives are available via the screener, along with tax-loss harvesting opportunities.